secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2022-03-24T23:59:59+00:00
Accession:  0000950170-22-004485
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.08, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen reports full-year 2021 net loss of $47.3M; on track for Phase 1 starts in Q3 2022
--------------------------------------------------------------------------------

- FY2021 net loss $47.3M vs $20.4M in 2020; R&D expenses $35.5M.
- Cash and equivalents $137.8M as of Dec 31, 2021.
- Phase 1 trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) expected to start Q3 2022.
- Nominated SZN-413, a Fzd4 bi-specific antibody, for retinal vascular diseases including wet AMD.
- 2022 Annual Meeting set for June 7, 2022; record date April 11, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017022004485/0000950170-22-004485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017022004485/srzn-20220321.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-004485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer